Early Stage Partners participated in the Series A early stage venture capital investment in HistoSonics, an Ann Arbor-based company that is commercializing histotripsy as a non-invasive method for ablating tissue. Histotripsy is the harnessing of micro-bubbles created by cavitation in fluid to destroy diseased tissue.
Recent Histosonics News
Histosonics Achieves Milestone With First Human Patient
Former FDA Commissioner von Eschenbach Joins Histosonics Board
U of Michigan Startup Raises $11 Million Early Stage Capital Investment
Histosonics Closes $11 Million Early Stage Venture Capital Investment
Find Out More About ESP
Mike Bunker manages Early Stage Partners' investment in HistoSonics